NFE2L2 and cancer: It is noteworthy that CB-839 dependent glutaminase inhibition, in the genetic context of KEAP1 mutation, suppressed tumor growth in a panel of human cancer cells with different origin, while NRF2 activation by KI696 treatment sensitized KEAP1-WT cells previously refractory to CB-839.